Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Daratumumab (Primary) ; RG 6146 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 11 Dec 2017 Planned End Date changed from 18 May 2019 to 15 Jan 2020.
- 11 Dec 2017 Planned primary completion date changed from 18 May 2019 to 15 Jan 2020.
- 09 Nov 2017 Planned End Date changed from 15 Jan 2020 to 18 May 2019.